- UID
- 1262765
- 在线时间
- 小时
- 注册时间
- 2017-2-14
- 最后登录
- 1970-1-1
- 主题
- 帖子
- 性别
- 保密
|
In countries in which new life-sustaining drugs cannot be patented, such drugs are sold at widely affordable prices; those same drugs, where patented, command premium prices because the patents shield patent-holding manufacturers from competitors. These facts show that future access to new life-sustaining drugs can be improved if the practice of granting patents on newly developed life-sustaining drugs were to be abolished everywhere.
Which of the following, if true, most seriously weakens the argument?
(A) In countries in which life-sustaining drugs cannot be patented, their manufacture is nevertheless a profitable enterprise.
(B) Countries that do not currently grant patents on life-sustaining drugs are, for the most part, countries with large populations.
(C) In some countries specific processes for the manufacture of pharmaceutical drugs can be patented even in cases in which the drugs themselves cannot be patented.
(D) Pharmaceutical companies can afford the research that goes into the development of new drugs only if patents allow them to earn high profits.
(E) Countries that grant patents on life-sustaining drugs almost always ban their importation from countries that do not grant such patents.
OA是D,我选了C
搜了很多网上的解释,说c讨论了其他专利,是无关的。但是我个人觉得,如果是制药过程有专利,那么消费者看到的药还是有“有专利”和“无专利”之分,那么他们还是会买有专利的,那么有专利的依然会比较贵,能够削弱结论。(我记得OG VERB上一有一个关于奶牛吃了某种食物增产的问题,答案也是C这个方向的)
反而对于D,我觉得,就算不能开发更新的药,但是题目问的是新药,现有的新药不也是新药吗?就算没有更新的药,现有的新药没有专利的分别以后,access不是还是会improve吗?
求大大们解惑...
|
|